GlassScriptPhysician profile
Milos Tomic
NPI 1427532993
$8,444.64
in general payments reported to CMS, 2019-2025
29 companies · $1,710 in 2025
The $1,710 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $848 · 2022: $1,401 · 2023: $2,450 · 2024: $2,036 · 2025: $1,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,094 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,093.98 |
| Education | $101.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,462.57 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,651.77 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $536.00 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $531.81 | 2021-2025 | Glassia, Hyqvia, Cuvitru |
| Genzyme Corporation | $526.50 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $505.42 | 2021-2025 | Opsumit, Uptravi |
| Mallinckrodt Hospital Products INC. | $402.93 | 2021-2025 | Acthar |
| Amgen INC. | $217.40 | 2021-2023 | Tezspire |
| Janssen Pharmaceuticals, INC | $188.42 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.62 | 2021-2025 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Pfizer INC. | $168.72 | 2021-2024 | |
| Genentech USA, INC. | $158.17 | 2022-2024 | Xolair |
| Optinose US, INC. | $156.07 | 2024 | |
| Merck Sharp & Dohme LLC | $87.60 | 2023-2025 | Winrevair |
| Jazz Pharmaceuticals INC. | $84.75 | 2021-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $80.82 | 2023-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Grifols USA, LLC | $67.93 | 2021-2023 | Prolastin-C Liquid |
| Insmed, INC. | $62.10 | 2022-2025 | Arikayce |
| Verona Pharma, INC. | $54.29 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $51.75 | 2022-2023 | Yupelri |
| Covis Pharma Gmbh | $43.50 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $38.92 | 2021 | |
| Electromed, INC. | $35.55 | 2023 | Smartvest |
| Abbvie INC. | $34.36 | 2024 | |
| Inogen, INC. | $31.11 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Advanced Respiratory, INC | $26.83 | 2021 | |
| Azurity Pharmaceuticals, INC. | $18.35 | 2025 | Alvesco |
| Otsuka America Pharmaceutical, INC. | $17.95 | 2025 | Rexulti |
| Hikma Pharmaceuticals USA | $17.43 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milos Tomic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.